See more : Intervacc AB (publ) (IVACC.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Apollo Endosurgery, Inc. (APEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Apollo Endosurgery, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Otco International Limited (OTCO.BO) Income Statement Analysis – Financial Results
- Zioncom Holdings Limited (8287.HK) Income Statement Analysis – Financial Results
- PolarX Limited (PXXXF) Income Statement Analysis – Financial Results
- Sports Toto Berhad (1562.KL) Income Statement Analysis – Financial Results
- Edoc Acquisition Corp. (ADOC) Income Statement Analysis – Financial Results
Apollo Endosurgery, Inc. (APEN)
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 76.86M | 62.99M | 42.05M | 50.71M | 60.85M | 64.31M | 64.87M | 1.60M | 5.08M | 7.99M | 6.69M | 9.39M | 7.84M | 11.91M | 2.86M | 372.35K | 511.86K | 743.27K |
| Cost of Revenue | 34.43M | 28.03M | 19.81M | 25.04M | 27.66M | 24.58M | 25.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 42.43M | 34.96M | 22.24M | 25.68M | 33.19M | 39.73M | 39.61M | 1.60M | 5.08M | 7.99M | 6.69M | 9.39M | 7.84M | 11.91M | 2.86M | 372.35K | 511.86K | 743.27K |
| Gross Profit Ratio | 55.20% | 55.50% | 52.90% | 50.63% | 54.55% | 61.78% | 61.07% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 11.91M | 9.52M | 7.67M | 10.38M | 12.18M | 8.30M | 7.81M | 8.51M | 18.13M | 11.34M | 8.16M | 9.73M | 7.82M | 6.63M | 10.12M | 12.42M | 4.04M | 1.48M |
| General & Administrative | 20.58M | 18.45M | 11.06M | 13.59M | 13.44M | 13.72M | 13.63M | 3.95M | 4.76M | 4.23M | 4.09M | 0.00 | 4.50M | 3.48M | 4.48M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 36.01M | 24.31M | 17.36M | 28.73M | 32.83M | 32.91M | 31.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 56.59M | 42.76M | 28.42M | 42.32M | 46.27M | 46.63M | 45.38M | 3.95M | 4.76M | 4.23M | 4.09M | 3.37M | 4.50M | 3.48M | 4.48M | 3.43M | 2.23M | 1.66M |
| Other Expenses | 1.75M | 1.88M | 1.95M | 2.10M | 7.07M | 7.24M | 7.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 70.25M | 54.16M | 38.04M | 54.80M | 65.52M | 62.17M | 60.37M | 12.46M | 22.89M | 15.58M | 12.25M | 13.10M | 12.32M | 10.11M | 14.60M | 15.85M | 6.28M | 3.15M |
| Cost & Expenses | 104.68M | 82.19M | 57.84M | 79.84M | 93.18M | 86.75M | 85.63M | 12.46M | 22.89M | 15.58M | 12.25M | 13.10M | 12.32M | 10.11M | 14.60M | 15.85M | 6.28M | 3.15M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 124.04K | 398.02K | 161.24K | 7.95K |
| Interest Expense | 4.67M | 8.32M | 5.25M | 4.05M | 4.06M | 4.51M | 18.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.12K | 27.95K | 0.00 | 157.13K |
| Depreciation & Amortization | -196.00K | 2.01M | 2.31M | 2.50M | 9.29M | 9.72M | 9.09M | 466.99K | 216.09K | 196.22K | 187.50K | 141.99K | 165.30K | 176.69K | 215.02K | 156.44K | 49.57K | 81.18K |
| EBITDA | -31.42M | -17.19M | -13.49M | -26.62M | -40.09M | -12.76M | -20.76M | -9.54M | -17.81M | -7.59M | -5.56M | -2.97M | 0.00 | 0.00 | -11.23M | -15.48M | -5.56M | -2.40M |
| EBITDA Ratio | -36.46% | -27.28% | -32.08% | -52.49% | -52.98% | -19.85% | -20.84% | -596.55% | -321.60% | -79.74% | -38.35% | -31.66% | -56.62% | 34.93% | -392.60% | -4,003.61% | -1,085.29% | -344.22% |
| Operating Income | -27.82M | -19.20M | -15.79M | -29.12M | -40.09M | -22.44M | -20.76M | -10.86M | -17.81M | -7.59M | -5.56M | -3.71M | -4.49M | 1.80M | -11.74M | -15.48M | -5.77M | -2.40M |
| Operating Income Ratio | -36.20% | -30.48% | -37.56% | -57.43% | -65.88% | -34.89% | -32.00% | -678.87% | -350.46% | -95.05% | -83.16% | -39.52% | -57.29% | 15.13% | -410.16% | -4,156.30% | -1,126.47% | -323.39% |
| Total Other Income/Expenses | -7.83M | -5.33M | -6.68M | 1.97M | -5.50M | -4.55M | -20.02M | 850.05K | 1.25M | 1.03M | 2.81M | 595.91K | -113.38K | 2.18M | 163.33K | 384.12K | 0.00 | -402.84K |
| Income Before Tax | -39.26M | -24.53M | -22.47M | -27.16M | -45.60M | -26.99M | -40.78M | -10.01M | -16.56M | -6.56M | -2.75M | -3.11M | -4.60M | 3.98M | -11.57M | -15.46M | 0.00 | -2.65M |
| Income Before Tax Ratio | -51.08% | -38.94% | -53.44% | -53.55% | -74.93% | -41.97% | -62.87% | -625.74% | -325.86% | -82.19% | -41.15% | -33.18% | -58.73% | 33.44% | -404.45% | -4,152.52% | 0.00% | -356.21% |
| Income Tax Expense | 584.00K | 156.00K | 142.00K | 275.00K | 191.00K | 304.00K | 387.00K | 850.05K | 1.25M | 1.03M | 2.81M | 595.91K | -113.38K | 2.18M | 175.45K | 42.00K | 0.00 | -86.79K |
| Net Income | -39.84M | -24.68M | -22.61M | -27.43M | -45.79M | -27.29M | -41.17M | -10.01M | -16.56M | -6.56M | -2.75M | -3.11M | -4.60M | 3.98M | -11.46M | -15.09M | -5.60M | -2.80M |
| Net Income Ratio | -51.84% | -39.18% | -53.77% | -54.09% | -75.24% | -42.44% | -63.46% | -625.74% | -325.86% | -82.19% | -41.15% | -33.18% | -58.73% | 33.44% | -400.54% | -4,053.13% | -1,094.97% | -376.28% |
| EPS | -0.98 | -0.82 | -0.99 | -1.27 | -2.31 | -2.01 | -105.69 | -29.95 | -77.00 | -37.61 | -19.74 | -26.65 | -44.48 | 39.63 | -128.50 | -209.81 | -123.52 | -365.69 |
| EPS Diluted | -0.98 | -0.82 | -0.99 | -1.27 | -2.31 | -2.01 | -105.69 | -29.95 | -77.00 | -37.61 | -19.74 | -26.65 | -44.48 | 37.78 | -128.50 | -209.81 | -123.52 | -365.69 |
| Weighted Avg Shares Out | 40.65M | 30.24M | 22.76M | 21.54M | 19.79M | 13.57M | 389.50K | 334.22K | 215.01K | 174.53K | 139.44K | 116.83K | 103.46K | 100.52K | 89.18K | 71.93K | 45.38K | 7.65K |
| Weighted Avg Shares Out (Dil) | 40.65M | 30.24M | 22.76M | 21.54M | 19.79M | 13.57M | 389.50K | 334.22K | 215.01K | 174.53K | 139.44K | 116.83K | 103.46K | 105.43K | 89.18K | 71.93K | 45.38K | 7.65K |
Apollo Endosurgery, Inc. to Report Second Quarter Results on July 23, 2019
AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the first quarter ended June 30, 2019...
Apollo Endosurgery, Inc. to Report First Quarter Results on May 2, 2019
AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the first quarter ended March 31, 2019...
Apollo Endosurgery, Inc. to Report Fourth Quarter Results on March 18, 2019
AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that the Company is scheduled to release its financial results for the fourth quarter ended December 31, 2018...
Apollo Endosurgery, Inc. Announces the Sale of Its Surgical Product Line
AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced the sale of its Surgical product line, which consists of the Lap-Band® adjustable gastric banding system and other...
Apollo Endosurgery, Inc. to Report Third Quarter Results on November 8, 2018
AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that the Company is scheduled to release its financial results for the third quarter ended September 30, 2018...
Apollo Endosurgery, Inc. to Report Second Quarter Results on August 8, 2018
AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that the Company is scheduled to release its financial results for the second quarter ended June 30, 2018...
Apollo Endosurgery, Inc. to Report First Quarter Results on May 3, 2018
AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that it plans to release its financial results for the first quarter ended March 31, 2018 on Thursday,...
Apollo Endosurgery, Inc. to Report Fourth Quarter and Full Year 2017 Results on March 1, 2018
AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that it plans to release its financial results for the fourth quarter and full year ended December 31, 2017...
Apollo Endosurgery to Report Third Quarter 2017 Financial Results on October 26, 2017
AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (NASDAQ:APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that it plans to release its third quarter 2017 financial results on Thursday, October 26, 2017 after the U.S....
Apollo Endosurgery Provides Update and Clarity to FDA Letter to Health Care Providers Related to Potential Risks of Intragastric Balloons
AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (NASDAQ:APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today provided an update and clarifications to a letter the U.S. Food and Drug Administration (FDA) sent to Health Care Providers...
Source: https://incomestatements.info
Category: Stock Reports